Balance Sheet Accounts and Supplemental Disclosures - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands |
Jun. 30, 2026 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|---|---|---|---|
| Balance Sheet Related Disclosures [Abstract] | |||
| Accrued compensation and related expenses | $ 5,872 | $ 11,094 | $ 8,449 |
| Accrued professional fees and other expenses | 4,411 | 4,796 | 839 |
| Accrued research, development and manufacturing expenses | 14,289 | 16,402 | 30,213 |
| Accrued for repurchase of common stock | 0 | 382 | 0 |
| Accrued liability - First Tracks Biotherapeutics | 4,226 | 0 | 0 |
| Total accrued expenses | $ 28,798 | $ 32,674 | $ 39,501 |